An Open-Label, Single-Arm Phase IV Study To Assess Ocrelizumab Efficacy, Safety, And Impact On Patient Reported Outcomes (PROS) In Patients With Active Relapsing Multiple Sclerosis
Phase of Trial: Phase IV
Latest Information Update: 16 Jan 2019
At a glance
- Drugs Ocrelizumab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms PRO-MSACTIVE
- Sponsors Roche
- 18 Sep 2018 Planned End Date changed from 15 Feb 2021 to 15 Sep 2021.
- 02 Aug 2018 Planned initiation date changed from 30 Jul 2018 to 8 Aug 2018.
- 02 Aug 2018 Status changed from not yet recruiting to recruiting.